Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500

Histone deacetylase 4 (HDAC4) is a protein encoded by the HDAC4 gene. It plays an important role in transcriptional regulation, cell cycle progression, and developmental events. The Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Development market research report provides an in-depth analysis of Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted pipeline therapeutics. The report provides comprehensive information on the Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.

Mechanisms of Action of Histone Deacetylase 4 Pipeline Market

The mechanisms of action of the Histone Deacetylase 4 pipeline market are Histone Deacetylase 4 Inhibitor and Histone Deacetylase 4 Activator.

Histone Deacetylase 4 pipeline market, by mechanisms of action

Histone Deacetylase 4 pipeline market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

Routes of Administration in Histone Deacetylase 4 Pipeline Market

The route of administration in the Histone Deacetylase 4 pipeline market is oral.

Molecule Types in Histone Deacetylase 4 Pipeline Market

The molecule types in the Histone Deacetylase 4 pipeline market are small molecule and gene therapy.

Histone Deacetylase 4 pipeline market, by molecule types

Histone Deacetylase 4 pipeline market, by molecule types

For more molecule type insights, download a free report sample

Key Histone Deacetylase 4 Pipeline Market Companies

The key companies in the Histone Deacetylase 4 pipeline market are 4SC AG, KYAN Therapeutics Inc, MEI Pharma Inc, and Mirati Therapeutics Inc.

Histone Deacetylase 4 pipeline market, by companies

Histone Deacetylase 4 pipeline market, by companies

To know more about key companies, download a free report sample

Market report overview

Mechanisms of Action Histone Deacetylase 4 Inhibitor and Histone Deacetylase 4 Activator
Routes of Administration Oral
Molecule Types Small Molecule and gene Therapy
Key Companies 4SC AG, KYAN Therapeutics Inc, MEI Pharma Inc, and Mirati Therapeutics Inc

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98).
  • Reviews of Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) therapeutics and enlists all their major and minor projects.
  • Assessment of Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98).

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98).
  • Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) – Overview

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) – Companies Involved in Therapeutics Development

4SC AG

KYAN Therapeutics Inc

MEI Pharma Inc

Mirati Therapeutics Inc

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) – Drug Profiles

Gene Therapy to Activate HDAC4 for Heart Failure – Drug Profile

Product Description

Mechanism Of Action

KYAN-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

MC-1568 – Drug Profile

Product Description

Mechanism Of Action

History of Events

mocetinostat – Drug Profile

Product Description

Mechanism Of Action

History of Events

pracinostat – Drug Profile

Product Description

Mechanism Of Action

History of Events

resminostat – Drug Profile

Product Description

Mechanism Of Action

History of Events

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) – Dormant Products

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) – Discontinued Products

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) – Product Development Milestones

Featured News & Press Releases

Jul 03, 2020: Helsinn and MEI stop Phase III trial of pracinostat in AML

May 13, 2020: Helsinn and MEI Pharma announce updated clinical data from the phase 2 study evaluating pracinostat in combination with azacitidine in patients with high/very-high risk myelodysplastic syndromes

Feb 14, 2019: Helsinn and MEI Pharma announce publication of phase II data for Pracinostat in combination with Azacitidine in the frontline treatment of older AML patients unfit for intensive chemotherapy, in Blood Advance

Jan 28, 2019: 4SC’s pivotal RESMAIN study of resminostat in CTCL receives second positive safety review

Dec 03, 2018: Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting

Nov 20, 2018: 4SC reaches significant milestone with enrollment of 100 patients in pivotal RESMAIN study of resminostat as CTCL maintenance therapy

Nov 09, 2018: Mirati presents data from ongoing phase 2 clinical trial of Mocetinostat in combination with Durvalumab at the SITC 33rd Annual Meeting

Nov 05, 2018: Mirati to present new data from ongoing phase 2 clinical trial on mocetinostat and durvalumab at the SITC 33rd Annual Meeting

Nov 01, 2018: MEI Pharma to present data from Phase 2 trial of Pracinostat at ASH 2018

Jun 28, 2018: New data supports resminostat’s mechanism of action in CTCL maintenance therapy

May 31, 2018: MEI Pharma and Helsinn Group Announce Successful Interim Analysis of Pracinostat/Azacitidine Phase 2 Combination Study in Higher Risk Myelodysplastic Syndrome (MDS) Patients

May 30, 2018: Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design of the Phase III PRIMULA study of Pracinostat in combination with azacitidine for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit f

Apr 19, 2018: Phase II study of 4SC’s resminostat in biliary tract cancer in Japan is initiated

Apr 11, 2018: Yakult Honsha recruits first Japanese patient in 4SC’s pivotal RESMAIN study of resminostat in CTCL

Mar 27, 2018: Yakult Honsha joins 4SC’s pivotal RESMAIN study of resminostat in CTCL – 4SC receives milestone payment

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by 4SC AG, 2022

Pipeline by KYAN Therapeutics Inc, 2022

Pipeline by MEI Pharma Inc, 2022

Pipeline by Mirati Therapeutics Inc, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.